Skip to main content

Table 1 Baseline characteristics

From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

Age (in years, at date of registration)
Mean 30.5
 Std 15.38
 Min 18
 Max 70
Gender  
 Male N=10, 83%
 Female N=2, 17%
Institution  
 DFCI N=4, 33.3%
 MGH N=8, 66.7%
Performance status  
 0 N=6, 50%
 1 N=6, 50%
Prior surgery  
 Yes N=9, 75%
 No N=3, 25%
Prior radiation
 Yes N=9, 75%
 No N=3, 25%
Number of prior radiation treatments
 N (patients) 9
 Mean (#prior treatments) 1.7
 Std 1.1
 Median 1.0
 Min 1
 Max 4
Prior Chemotherapy  
 Yes N=12, 100%
Number of prior chemotherapy treatments  
 N (patients) 12
 Mean (#prior treatments) 6.5
 Std 6.4
 Median 5
 Min 1
 Max 20